Penumbra Revenue 2011-2026 | PEN

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Penumbra

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
1.4 B	1.19 B	1.06 B	847 M	748 M	560 M	547 M	445 M	334 M	263 M	186 M	126 M	88.8 M	73.1 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.4 B	73.1 M	562 M

Quarterly Revenue Penumbra

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
355 M	339 M	324 M	301 M	299 M	279 M	271 M	261 M	241 M	-	214 M	208 M	204 M	204 M	190 M	184 M	169 M	167 M	151 M	105 M	137 M	145 M	140 M	134 M	128 M	121 M	112 M	110 M	103 M	96.1 M	83.9 M	80.6 M	73.2 M	73.1 M	67.2 M	65.1 M	57.9 M	54.4 M	50.4 M	42.3 M	39 M	35.4 M	32.5 M	31.5 M	26.2 M	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
355 M	26.2 M	148 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Medical devices industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
BIOLASE BIOL	49.2 M	-	-13.19 %	$ 166 K	USA
GenMark Diagnostics, Inc. GNMK	172 M	-	-	$ 1.77 B	USA
Allied Healthcare Products AHPI	6.02 M	-	3.58 %	$ 2.21 M	USA
Eargo EAR	37.2 M	-	-	$ 10.2 M	USA
Apollo Endosurgery APEN	76.9 M	-	-	$ 475 M	USA
Obalon Therapeutics, Inc. OBLN	1.59 M	-	-5.86 %	$ 30.6 M	USA
Delcath Systems DCTH	85.2 M	$ 11.34	2.9 %	$ 406 M	USA
Second Sight Medical Products EYES	1 K	-	-0.97 %	$ 54.4 M	USA
Electromed ELMD	64 M	$ 25.21	-1.37 %	$ 213 M	USA
Avinger AVGR	7.65 M	-	-20.74 %	$ 369 K	USA
Axonics Modulation Technologies AXNX	274 M	-	-	$ 3.31 B	USA
Aziyo Biologics AZYO	12.3 M	-	1.37 %	$ 20.5 M	USA
EDAP TMS S.A. EDAP	44.1 M	$ 3.49	2.95 %	$ 131 M	France
BioSig Technologies BSGM	40 K	-	37.08 %	$ 85.7 M	USA
Helius Medical Technologies HSDT	644 K	$ 2.15	-0.23 %	$ 1.31 M	USA
Conformis CFMS	62 M	-	-	$ 16.4 M	USA
Inspire Medical Systems INSP	912 M	$ 45.61	-16.83 %	$ 1.34 B	USA
ClearPoint Neuro CLPT	37 M	$ 10.97	-1.88 %	$ 311 M	USA
Cardiovascular Systems CSII	236 M	-	0.15 %	$ 844 M	USA
Cytosorbents Corporation CTSO	37.1 M	$ 0.63	0.87 %	$ 39.2 M	USA
CryoLife, Inc. CRY	253 M	-	-4.14 %	$ 702 M	USA
LivaNova PLC LIVN	1.39 B	$ 57.75	-2.23 %	$ 3.15 B	Britain
Invacare Corporation IVC	181 M	-	-	$ 24.7 M	USA
Hancock Jaffe Laboratories, Inc. HJLI	4.25 K	-	-1.98 %	$ 98.3 M	USA
Itamar Medical Ltd. ITMR	41 M	-	0.03 %	$ 1.58 B	Israel
IRIDEX Corporation IRIX	52.7 M	$ 1.07	-1.38 %	$ 18.1 M	USA
Dynatronics Corporation DYNT	27.4 M	-	14.99 %	$ 929 K	USA
Misonix, Inc. MSON	62.5 M	-	-	$ 462 M	USA
Neovasc NVCN	2.55 M	-	-	$ 111 M	Canada
OrthoPediatrics Corp. KIDS	236 M	$ 16.1	2.03 %	$ 378 M	USA
Butterfly Network BFLY	82.1 M	$ 4.95	2.06 %	$ 1.05 B	USA
Intersect ENT, Inc. XENT	80.6 M	-	-	$ 955 M	USA
Sintx Technologies SINT	1.02 M	$ 2.38	-1.65 %	$ 6.6 M	USA
GBS GBS	3.05 M	-	-0.57 %	$ 7.12 M	USA
Globus Medical GMED	2.94 B	$ 91.11	0.56 %	$ 12.3 B	USA
NanoVibronix NAOV	2.55 M	-	-	$ 1.08 M	USA
CONMED Corporation CNMD	1.37 B	$ 35.98	0.28 %	$ 1.12 B	USA
TransMedics Group TMDX	605 M	$ 97.27	0.2 %	$ 3.31 B	USA
Tandem Diabetes Care TNDM	290 M	$ 19.32	-2.77 %	$ 1.31 B	USA
Integer Holdings Corporation ITGR	1.85 B	$ 87.19	3.86 %	$ 3.03 B	USA
Stryker Corporation SYK	7.17 B	$ 292.65	0.61 %	$ 112 B	USA
Edwards Lifesciences Corporation EW	6.07 B	$ 82.62	-0.85 %	$ 48.3 B	USA
LENSAR LNSR	58.4 M	$ 5.51	-0.9 %	$ 65.9 M	USA
Pulmonx Corporation LUNG	90.5 M	$ 1.26	-4.89 %	$ 51.3 M	USA
MiMedx Group MDXG	419 M	$ 3.65	0.97 %	$ 539 M	USA
Myomo MYO	40.9 M	$ 0.85	-1.94 %	$ 35.6 M	USA
Cutera CUTR	49.5 M	-	-10.19 %	$ 1.99 M	USA